Novosibirsk · Russian-qualified counsel Recognised by Pravo-300 · Best Lawyers · Kommersant
Restructuring & Insolvency

Regulatory update: pre-packaged restructuring options under Russian law in the pharmaceuticals sector

Stanislav Lastovsky · May 2026 · 9 min read

Russia's restructuring law offers pre-packaged options for pharma-sector creditors. What foreign pharma creditors need to know. Make an enquiry.

Following recent legislative and judicial developments in Russia, foreign creditors holding claims against pharmaceutical companies face a materially changed restructuring landscape. Pre-packaged restructuring options under Russian law — long available in principle under the general insolvency framework — have acquired a new practical significance in the pharmaceuticals sector, where state licensing requirements, EAEU regulatory obligations, and strategic-enterprise considerations interact with the creditor's procedural rights. For foreign trade creditors and institutional investors tracking their pharmaceutical-sector exposures, understanding what the Russian framework now offers, and where its constraints lie, is an increasingly pressing task.

§ I. What changed — the shift in Russian pre-packaged restructuring practice

Pre-packaged restructuring, in the Russian context, refers to arrangements under which the principal creditors and the debtor reach substantive agreement on a debt restructuring plan before formal insolvency proceedings are opened — or, at the latest, at the early stage of those proceedings — with the intention that the plan be confirmed by the court on an accelerated basis. The mechanism is not a standalone statutory procedure but rather an approach that creditors have developed under the flexible provisions of Russian insolvency legislation governing financial recovery plans and creditor agreements.

What has shifted in the period up to October 2026 is principally a matter of judicial receptiveness and regulatory framing. Russian arbitrazh courts have, in the prevailing practice, become more willing to confirm pre-negotiated financial recovery plans in pharmaceutical-sector matters where the debtor holds licences essential to continued operations — on the basis that liquidation of a licensed pharmaceutical manufacturer or distributor carries systemic consequences that courts have shown willingness to weigh. Roszdravnadzor (the Federal Service for Health Surveillance) has reinforced this dynamic by issuing administrative guidance indicating that licensing continuity during restructuring proceedings is a factor it considers when deciding whether to suspend or revoke pharmaceutical licences following an insolvency filing.

Creditors who previously assumed that a Russian pharmaceutical debtor facing liquidity pressure could only be resolved through bankruptcy liquidation should review that assumption. The practical conditions for a pre-packaged outcome have, in the assessment of counsel experienced in this sector, improved meaningfully.

For creditors assessing a pharmaceutical-sector exposure in Russia, early legal advice on the restructuring options available can be determinative. Make an enquiry: info@vetrovpartners.com |

§ II. Who is affected — and why the pharmaceuticals sector is different

The shift carries distinct implications depending on a creditor's position in the capital or trade structure. Three categories of foreign creditor are most directly affected.

Foreign trade creditors holding unpaid supply claims against Russian pharmaceutical distributors or manufacturers occupy the most immediately relevant position. Where a debtor holds pharmaceutical licences and distribution authorisations under both Russian federal law and the relevant EAEU pharmaceutical regulatory framework, the going-concern value of that debtor — and therefore the recoverable value for trade creditors in a restructuring — materially exceeds its liquidation value. A pre-packaged or pre-negotiated restructuring plan that preserves operational continuity will, in most circumstances, generate a better recovery for trade creditors than a liquidation scenario. The practical difficulty has historically been that foreign creditors lacked the leverage and procedural standing to promote a restructuring outcome; this is the position that has shifted.

Foreign institutional creditors holding secured debt — whether under pledge arrangements over pharmaceutical inventory, intellectual property associated with registered drug products, or real-estate assets used in manufacturing — face a more textured analysis. Under Russian insolvency legislation, secured creditors retain preferential distribution rights in liquidation, but in a restructuring plan secured creditors may be asked to accept modified terms in exchange for plan confirmation. Courts have generally required that secured creditors receive, at minimum, the expected liquidation value of their collateral under any confirmed plan — though the precise treatment remains subject to judicial discretion and the composition of the creditor committee.

EAEU-based creditors holding claims arising from cross-border pharmaceutical supply arrangements face the additional question of how EAEU-level pharmaceutical regulatory requirements interact with the Russian insolvency timeline. The EAEU's harmonised pharmaceutical legislation establishes registration and quality-certification standards that continue to apply to the debtor entity during Russian insolvency proceedings. In practice, this means that a pharmaceutical debtor in Russian restructuring proceedings remains subject to EAEU inspection and certification obligations — a factor that can support the going-concern case for pre-packaged restructuring, but that also introduces regulatory risk if the debtor's compliance capacity is impaired by the financial situation.

Foreign creditors whose claims arose under contracts governed by a law other than Russian law should note that, under the prevailing approach of Russian arbitrazh courts, the insolvency proceedings themselves are governed by Russian law regardless of the governing law of the underlying contract. The creditor's substantive claim is recognised in Russian proceedings, but the procedures, timelines, and distribution rules applicable in those proceedings are Russian.

Note: Foreign creditors who delay filing their claims in Russian insolvency proceedings risk losing their place in the creditor register. Under Russian insolvency legislation, claims filed outside the statutory window are relegated to a lower-priority queue for distribution — a consequence that creditors unfamiliar with Russian procedural timelines frequently underestimate, and one that cannot be remedied after the window closes.

"Pre-packaged restructuring in the Russian pharmaceutical sector is not a theoretical option — it is a workable outcome for creditors who move early and secure adequate procedural standing before the insolvency filing is made." — Stanislav Lastovsky, Senior Lawyer, Practice Lead — Restructuring & Insolvency, Vetrov & Partners

Institutional and trade creditors holding Russian pharmaceutical-sector claims should establish their procedural position before formal insolvency proceedings are opened — not after. Speak to our team: info@vetrovpartners.com |

§ III. What foreign creditors should do now

The practical steps for a foreign creditor assessing a pharmaceutical-sector exposure in Russia follow from the analysis above. Three immediate priorities stand out.

First, map the debtor's regulatory position. A pharmaceutical debtor's going-concern value is inseparable from its licence and registration portfolio. Creditors should obtain — through Russian counsel — a clear picture of which federal and EAEU licences the debtor holds, the risk profile of those licences in an insolvency scenario, and whether the debtor qualifies as a strategically significant enterprise under Russian law (a designation that can affect the procedure available and the involvement of state authorities). This mapping exercise directly informs the creditor's restructuring strategy.

Second, assess pre-packaged viability before formal proceedings are opened. The window for meaningful creditor influence over a restructuring outcome is typically widest before a formal insolvency application is filed. Once formal bankruptcy proceedings commence in Russia, the debtor's management is progressively displaced, the court-appointed insolvency administrator assumes operational control, and the creditor's ability to negotiate plan terms directly with the debtor is constrained. Foreign creditors who engage early — and who instruct Russian counsel to approach the debtor's management or principal domestic creditors before a filing — are in a materially stronger position than those who respond reactively.

Third, verify claim documentation and enforceability under Russian law. Pre-packaged restructuring in Russia requires that participating creditors hold claims that are legally enforceable in Russian proceedings. Foreign creditors should not assume that a contract governed by English or German law, or a judgment or arbitral award obtained in a foreign jurisdiction, will automatically translate into a usable claim in Russian proceedings without procedural steps. Our detailed guidance on the specific steps for enforcing foreign claims in Russian insolvency proceedings is set out in Pre-packaged restructuring options under Russian law and Strategic considerations in pre-packaged restructuring. The firm's Restructuring & Insolvency practice page sets out the full scope of creditor-side advisory work the team undertakes.

§ IV. Open questions — what remains unsettled

Several aspects of the framework remain subject to evolving practice or pending regulatory clarification, and foreign creditors should factor these into their planning.

The interaction between Russia's strategic-enterprise regime and pre-packaged restructuring in the pharmaceutical sector is not uniformly settled. Where a pharmaceutical company is designated as strategically significant — a category that can apply to manufacturers of essential or state-procured medicines — the insolvency proceedings may require specific government approvals before a restructuring plan can be confirmed. The precise conditions for, and timing of, any such approvals have not been codified in a way that makes the outcome predictable in all cases. Counsel experienced in the sector can provide a case-specific assessment.

The treatment of EAEU-registered drug products in a restructuring — specifically, whether the registration dossier and associated intellectual property can be included in a plan that involves a transfer of business or assets to a restructured entity — has been addressed in a limited number of Russian court decisions, and the position is not yet uniformly established. The Matters section of this website includes anonymised descriptions of matters in which the firm has advised creditors on asset-specific issues in Russian pharmaceutical-sector insolvencies.

Finally, the applicability of any amendments to Russia's insolvency framework that may be enacted following publication of this update should be verified with Russian counsel. The legislative position in this area continues to develop, and the analysis in this piece reflects the framework as understood as of the date of publication.

Frequently asked questions

Q: What specifically changed in Russian pre-packaged restructuring practice relevant to the pharmaceuticals sector?

A: Russian arbitrazh courts have shown greater willingness to confirm pre-negotiated restructuring plans for pharmaceutical debtors — particularly where the debtor holds operating licences whose value would be destroyed in a liquidation. Roszdravnadzor has also indicated that licensing continuity during restructuring is a factor in its administrative decision-making. Together, these developments have improved the practical conditions for creditors seeking a pre-packaged outcome, compared with the position under earlier practice where liquidation was more often the default path.

Q: Which foreign creditors are most affected by this development?

A: Foreign trade creditors holding supply-chain claims against Russian pharmaceutical companies, and foreign institutional creditors with secured positions over pharmaceutical assets, are the most directly affected. EAEU-based creditors with cross-border pharmaceutical supply claims face an additional layer of analysis, given the interaction between EAEU pharmaceutical regulatory requirements and the Russian insolvency timeline. In all cases, the critical variable is whether the creditor has filed its claim within the statutory window in Russian proceedings — a procedural step that cannot be deferred without significant risk to recovery priority.

Q: What should foreign creditors do to protect their position under the current framework?

A: Foreign creditors should take three steps: map the Russian debtor's regulatory and licence position through Russian counsel; assess whether a pre-packaged restructuring approach is viable before formal insolvency proceedings are opened; and verify that their underlying claims are enforceable in Russian proceedings. Creditors who act before the formal insolvency filing have the widest range of options. Once proceedings are opened, the scope for creditor-driven outcomes narrows materially. The firm's Restructuring & Insolvency team advises foreign creditors on creditor-side mandates of this type.

Practitioner note

This briefing is general information and does not constitute legal advice. For advice on a specific matter, write in confidence to info@vetrovpartners.com.

Facing a matter like this?

Our team advises foreign clients on exactly these questions across Russia and the EAEU region. Initial 30-minute consultation — complimentary.

Make an enquiry